Why Value-based Contracts Are Still the Exception, per Chester "Bernie" Good at UPMC
October 17th 2022Chester "Bernie" Good, senior medical director for the Center for Value Based Pharmacy Initiatives at UPMC Health Plan, gets in depth on value-based contracts and shares the results of the 2019 contract between UPMC and AstraZeneca for Brilinta. Good addressed value-based contracts last week at AMCP Nexus 2022 conference in National Harbor, Maryland.
Read More
Will Keytruda and Opdivo Finally Get Some Price Competition? | AMCP Nexus 2022
October 14th 2022EQRx has said it will price its PD-1/PDL-1 inhibitor 40% below the price of the entrenched PD-1/PDL-1 inhibitors, says Bhavesh Shah of Boston Medical Center Health System. But there are obstacles looming, including the development of combination therapies.
Read More
How to Make Accumulator, Maximizer Programs More Acceptable to Your Patients l AMCP Nexus 2022
October 14th 2022Julie Kendle, Director, Clinical Pharmacy Director, Clinical Pharmacy at IPD Analytics addresses tips on improving accumulators and ways for PBMs or payers to make their accumulator and maximizer programs more acceptable to patients. Kendle spoke at this year's AMCP Nexus meeting in National Harbor, Maryland.
Read More
Trikafta Effective But Costly, Says Prime Therapeutics | AMCP Nexus 2022
October 14th 2022A real-world study by the PBM shows major benefits from the new cystic fibrosis drug when it comes to hospitalizations and pulmonary exacerbations. But total cost of care of patients tripled because the drug is expensive.
Read More
Gene Therapy Has Arrived. But So Will the $$$$$ Bills. | AMCP Nexus 2022
October 13th 2022Express Scripts' Aimee Tharaldson discussed the growing number of gene therapies in her keynote talk today on specialty drug at AMCP Nexus 2022. She listed 12 approved gene therapies, eight in the near-term pipeline for hemophilia and another seven for other diseases that may be approved next year.
Read More
Accumulators, Maximizers Exacerbate Healthcare Disparities, Says Janssen Research | AMCP Nexus 2022
October 13th 2022Research by Janssen shows that non-White patients are disproportionately affected by the accumulators and maximizers that PBMs use to blunt the financial consequences of copay assistance cards.
Read More
Digital Therapeutics Should Have More to Come in Healthcare by 2023 | AMCP Nexus 2022
October 13th 2022Kelly Price, vice president of market access for Mahana Therapeutics, compared the difference between digital therapeutics, prescription digital therapeutics and how FDA approval factors into that difference. She also shared what's hopeful and what's to come as far as coverage decisions, rule changes and FDA guidance for digital therapeutics in 2023.
Read More
What You Need To Know About Medicare Part B Step Therapy: AMCP Nexus 2022
October 12th 2022Yuqian Liu, Pharm.D., and Michelle Booth, Pharm.D., of Magellan Rx Management, discuss the background and consequences of step therapy in Medicare Part B in an interview prior to their session at the AMCP Nexus 2022 meeting in National Harbor, Maryland.
Read More
The former Baltimore city health commissioner has been criticized for some of her views on COVID-19 mandates. In her talk opening the AMCP Nexus 2022 meeting, Wen said that if public health officials don’t take into account public attitudes, it could affect the ability to deal with future public health emergencies.
Read More
AMCP Nexus 2021: What’s Promising, What’s Problematic About Prescription Digital Therapeutics
October 21st 2021A panel discussion on prescription digital therapeutics identified them as a sweet spot for value-based agreements and collection of real-world evidence. But should they be paid for through the pharmacy benefit? And is there enough evidence available for payers and PBMs to make sound coverage and formulary decisions? For answers, stay tuned.
Read More
AMCP Nexus 2021: How SCAN Turned Healthcare Disparity Talk Into Action
October 20th 2021The Southern California Medicare Advantage health plan zeroed in on medication adherence among its Black and Latinx members and took a multifaceted approach, which included cultural humility training and pairing staff and members had language and a cultural background in common.
Read More
Loucks, manager of specialty clinical pharmacy programs and formulary at Kaiser Permanente Washington, discusses metrics that might give healthcare providers an incentive to address healthcare disparities and concrete steps that could be taken to turn the talk about addressing healthcare disparities into a reality.
Read More